

**Our Mission**  
Bridging the gap  
from target to lead

## The bridging company

YUMAB is a privately-held German CRO with a subsidiary in the US.

We set out in 2012 to bridge the gap between research innovation and novel therapies by establishing an advanced discovery platform that provides access to challenging targets, enables new formats, and accelerates the development of human antibodies at a high success rate.

One of our greatest assets are our large natural human antibody libraries (>10<sup>11</sup>), patient derived or immune libraries (also from different animal species).

## Proven track record

Our contract research and partnered development has been proven by >200 projects over the past 11 years with >120 clients and collaboration partners worldwide.

YUMABs spin-out CORAT Therapeutics developed the novel safety optimized human antibody COR-101 to treat COVID-19 in hospitalized patients. The project took only 4.5 months from target to final lead and 11 months to the start of the clinical development.

## Our service pledge

We support your race towards novel and better immunotherapeutics with ultra-fast track discovery and specialized engineering technologies. From target discovery to fully characterized lead - our experienced team leads biotech and pharma teams worldwide through the development process as your trusted, de-risking partner!

**Let's discuss your needs in  
antibody drug discovery!**  
[info@yumab.com](mailto:info@yumab.com)

# A HUMAN THERAPEUTIC ANTIBODY PLATFORM TO ACCELERATE THE DEVELOPMENT OF NEXT-GENERATION BIOTHERAPEUTICS


## POWERFUL LIBRARY TECHNOLOGY

### Fully human derived antibody libraries combined with powerful in vitro selection

- natural and fully human antibody repertoire (CDRs, FRs, VH germline distribution)
- highly diverse (10<sup>11</sup>)
- in vitro antibody selection for pre-designed antibody properties
- HT screening with soluble antibodies on antigens and cells
- proven functionality to more than 600 different (mostly human) antigens

## ENABLING PLATFORM

### Connecting target innovation with clinical development



## CUSTOM SERVICES – RAPID, ROBUST, RELIABLE



### Custom-made state-of-the-art antibody libraries

- universal and fully human
- huge diversity, in vivo or variable germline distribution
- library stocks, antibody-phage and manuals provided



### Customizable antibody formats

- fully human IgG
- recombinant formats
- all isotypes and chimeric variants



### Antibody analysis

- biological activity
- biochemical characterization



### Human antibody discovery by antibody-phage display

- in vitro antibody selection for pre-designed antibody properties
- all antigen types
- HT screening with soluble antibodies on antigens & cells



### Production & purification

- in house throughput antibody production
- purification
- testing & validation



### Antibody engineering

- in vitro evolution technologies (light chain shuffling, mutagenesis)
- rational design
- bioinformatic optimization

**YUMAB**

## YUMAB At a glance

### Ultra-fast hit discovery

- natural antibody sequences from superior universal human germline libraries
- direct, targeted in vitro selection on target molecules and/or cells within weeks
- no animal use, low toxicity and immunogenicity

### Advanced research

- versatile, universally applicable technology
- smooth translation from bench to bedside
- innovative research and diagnostic tools

### Efficient lead development

- close-to-germline candidates
- all antibody formats, all therapeutic indications
- robust process, high success rates

### Flexible collaboration

- CRO: Fee-for-service projects and flexible license options
- collaborative development
- out-licensing of internal lead candidates

**Get more info on our website**

